hasIndication
P23161
predicate
Indicates that one entity (typically a product, treatment, or intervention) is intended, approved, or suitable for use in addressing, preventing, or managing a particular condition, purpose, or circumstance.
All labels observed (15)
| Label | Occurrences |
|---|---|
| indication | 265 |
| hasIndication canonical | 169 |
| approvedForIndication | 14 |
| hasIndicationDetail | 6 |
| hasHealthIndication | 5 |
| hasIndicationType | 5 |
| hasPrimaryIndication | 5 |
| indicationType | 5 |
| hasDrugIndication | 3 |
| hasIndicationRegion | 3 |
| hasFDALabelIndication | 2 |
| indicationSubtype | 2 |
| isIndicatedWhen | 2 |
| hasIndicationStatus | 1 |
| leadProductIndication | 1 |
Description generation (PDg)
The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.
Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning. # Instructions Focus on describing the relationship, not the entities themselves. # Response Format Begin the description with \' Indicates...\'
Input
Predicate: hasIndication
Generated description
Indicates that one entity (typically a product, treatment, or intervention) is intended, approved, or suitable for use in addressing, preventing, or managing a particular condition, purpose, or circumstance.
Sample triples (488)
| Subject | Object |
|---|---|
| Leqembi |
Alzheimer's disease
ⓘ
surface form:
Alzheimer’s disease
|
| Leqembi | mild cognitive impairment due to Alzheimer’s disease ⓘ |
| Leqembi | mild dementia stage of Alzheimer’s disease ⓘ |
| Tysabri | relapsing forms of multiple sclerosis in adults via predicate surface "approvedForIndication" ⓘ |
| Tysabri | inducing and maintaining clinical response in adults with Crohn’s disease via predicate surface "approvedForIndication" ⓘ |
| Aduhelm | Alzheimer's disease via predicate surface "indication" ⓘ |
| Aduhelm | mild cognitive impairment due to Alzheimer's disease via predicate surface "indication" ⓘ |
| Aduhelm | mild Alzheimer's disease dementia via predicate surface "indication" ⓘ |
| Lucentis | vision preservation via predicate surface "hasIndicationType" ⓘ |
| Lucentis | treatment of choroidal neovascularization via predicate surface "hasIndicationType" ⓘ |
| Tecentriq | non-small cell lung cancer via predicate surface "indication" ⓘ |
| Tecentriq | small cell lung cancer via predicate surface "indication" ⓘ |
| Tecentriq | urothelial carcinoma via predicate surface "indication" ⓘ |
| Tecentriq | triple-negative breast cancer via predicate surface "indication" ⓘ |
| Tecentriq | hepatocellular carcinoma via predicate surface "indication" ⓘ |
| Tecentriq | melanoma via predicate surface "indication" ⓘ |
| Tecentriq | various solid tumors expressing PD-L1 via predicate surface "indication" ⓘ |
| Tecentriq | metastatic non-small cell lung cancer via predicate surface "indicationSubtype" ⓘ |
| Tecentriq | locally advanced or metastatic urothelial carcinoma via predicate surface "indicationSubtype" ⓘ |
| Xarelto | prevention of stroke in nonvalvular atrial fibrillation ⓘ |
| Xarelto | treatment of deep vein thrombosis ⓘ |
| Xarelto | treatment of pulmonary embolism ⓘ |
| Xarelto | reduction in the risk of recurrence of DVT and PE ⓘ |
| Xarelto | prophylaxis of venous thromboembolism after hip replacement surgery ⓘ |
| Xarelto | prophylaxis of venous thromboembolism after knee replacement surgery ⓘ |
| Xarelto | reduction of risk of major cardiovascular events in patients with chronic coronary artery disease ⓘ |
| Xarelto | reduction of risk of major cardiovascular events in patients with peripheral artery disease ⓘ |
| Xarelto | treatment of venous thromboembolism in pediatric patients ⓘ |
| Xarelto | thromboprophylaxis in acutely ill medical patients at risk for thromboembolic complications ⓘ |
| Janssen COVID-19 Vaccine | prevention of COVID-19 in humans via predicate surface "indication" ⓘ |
| Imbruvica |
United States of America
via predicate surface "hasIndicationRegion"
ⓘ
surface form:
United States
|
| Imbruvica | European Union via predicate surface "hasIndicationRegion" ⓘ |
| Avastin | oncology via predicate surface "indicationType" ⓘ |
| Perjeta | HER2-positive metastatic breast cancer via predicate surface "indication" ⓘ |
| Perjeta | HER2-positive early breast cancer via predicate surface "indication" ⓘ |
| Perjeta | HER2-positive locally advanced breast cancer via predicate surface "indication" ⓘ |
| oseltamivir | uncomplicated acute illness due to influenza infection ⓘ |
| oseltamivir | post-exposure prophylaxis of influenza ⓘ |
| Alnylam Pharmaceuticals | hereditary transthyretin-mediated amyloidosis ⓘ |
| Alnylam Pharmaceuticals | acute hepatic porphyria ⓘ |
| Alnylam Pharmaceuticals | primary hyperoxaluria type 1 ⓘ |
| Alnylam Pharmaceuticals | polyneuropathy of hereditary transthyretin-mediated amyloidosis ⓘ |
| REGN-EB3 | treatment of infection caused by Zaire ebolavirus via predicate surface "indication" ⓘ |
| REGN-EB3 | treatment of Ebola virus disease in adults via predicate surface "indication" ⓘ |
| REGN-EB3 | treatment of Ebola virus disease in pediatric patients via predicate surface "indication" ⓘ |
|
memantine
surface form:
Memantine
|
moderate to severe Alzheimer’s disease via predicate surface "indication" ⓘ |
|
memantine
surface form:
Memantine
|
Alzheimer’s-type dementia via predicate surface "indication" ⓘ |
| COVID-19 vaccines | prevention of symptomatic COVID-19 via predicate surface "indication" ⓘ |
| COVID-19 vaccines | prevention of severe COVID-19 via predicate surface "indication" ⓘ |
| COVID-19 vaccines | prevention of COVID-19-related hospitalization via predicate surface "indication" ⓘ |